| Nov 5 |
Syndax: Q3 Earnings Snapshot
|
| Nov 5 |
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 5 |
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
|
| Nov 5 |
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
|
| Nov 5 |
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
|
| Nov 4 |
Syndax Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 4 |
Syndax, Royalty Pharma enter into $350M royalty funding deal
|
| Nov 4 |
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
|
| Nov 1 |
Syndax Announces Participation in November Investor Conferences
|
| Oct 29 |
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
|
